Dabigatran versus warfarin in patients with atrial fibrillation [4]

New England Journal of Medicine

Volumn 361, Issue 27, 2009, Pages 2672-2673

  Worthington, John M ^a   Gattellari, Melina ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

BLEEDING; DRUG EFFICACY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; AGED; CHEMICALLY INDUCED DISORDER; MORTALITY; NOTE; PATIENT;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; HEMORRHAGE; HUMANS; PATIENT DROPOUTS; PYRIDINES; WARFARIN;

EID: 74049163764     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493503.
2. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599607.
3. Lippi G, Franchini M, Targher G. Rivaroxaban for thrombo-prophylaxis. N Engl J Med 2008;359:2174.